Percutaneous transfemoral management of severe secondary tricuspid regurgitation with edwards sapien XT bioprosthesis: First-in-man experience

摘要

Severe tricuspid regurgitation (TR) is associated with increased morbidity and mortality. In advanced TR stages, right-sided heart failure, ascites, and congestive hepatopathy increase surgical risk (1); alternative approaches are therefore required.Transcatheter valve procedures are increasingly applied in clinical practice to treat aortic, mitral, and pulmonary valve diseases (2,3). Few data are available, however, on percutaneous treatment of the tricuspid valve regurgitation (TV). The specific approach to implant two valves in the superior and inferior vena cava (IVC) was originally proposed by Davidson et al. (4). One human case report described successful transcatheter treatment of TR with a customized, self-expanding heart valve for IVC implantation (5).